Everest Approved to Launch Antibiotic in China for Intra-Abdominal Infections
publication date: Mar 16, 2023
Shanghai Everest Medicines announced Xerava® (eravacycline) was approved in China to treat complicated intra-abdominal infections in adult patients. Xerava, which will be Everest’s first commercialized drug, is a novel parenteral broad-spectrum, fluorocycline antibiotic of the tetracycline class. It has shown broad in vitro activity against Gram-negative and Gram-positive pathogens with multidrug resistance. In 2018, Everest in-licensed Greater China rights for Xerava from Boston’s Tetraphase Pharma in a $43 million agreement. Xerava is already approved in the US, EU and other parts of the world. More details....
Stock Symbol: (HK 1952)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.